
Terry A. Wallace
Examiner (ID: 8615, Phone: (571)272-2630 , Office: P/2916 )
| Most Active Art Unit | 2916 |
| Art Unit(s) | 2912, 2900, 2902, 2916 |
| Total Applications | 11456 |
| Issued Applications | 11361 |
| Pending Applications | 3 |
| Abandoned Applications | 90 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 20357573
[patent_doc_number] => 12473560
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-11-18
[patent_title] => Antigen binding molecules targeting SARS-CoV-2
[patent_app_type] => utility
[patent_app_number] => 18/151088
[patent_app_country] => US
[patent_app_date] => 2023-01-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 10
[patent_figures_cnt] => 10
[patent_no_of_words] => 17592
[patent_no_of_claims] => 14
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 124
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18151088
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/151088 | Antigen binding molecules targeting SARS-CoV-2 | Jan 5, 2023 | Issued |
Array
(
[id] => 18351423
[patent_doc_number] => 20230139534
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-05-04
[patent_title] => METHODS OF TREATING GRAFT VERSUS HOST DISEASE USING IL-2 MUTEINS
[patent_app_type] => utility
[patent_app_number] => 18/068970
[patent_app_country] => US
[patent_app_date] => 2022-12-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5605
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -8
[patent_words_short_claim] => 32
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18068970
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/068970 | Methods of treating graft versus host disease using IL-2 muteins | Dec 19, 2022 | Issued |
Array
(
[id] => 18673113
[patent_doc_number] => 20230310591
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-10-05
[patent_title] => Vaccine Boost Methods and Compositions
[patent_app_type] => utility
[patent_app_number] => 18/062817
[patent_app_country] => US
[patent_app_date] => 2022-12-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13228
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18062817
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/062817 | Vaccine Boost Methods and Compositions | Dec 6, 2022 | Abandoned |
Array
(
[id] => 18692578
[patent_doc_number] => 20230322879
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-10-12
[patent_title] => CYTOKINE-BASED MULTI-EPITOPE PROTEIN FOR BINDING TO CCR7-POSITIVE CELLS
[patent_app_type] => utility
[patent_app_number] => 18/073599
[patent_app_country] => US
[patent_app_date] => 2022-12-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9408
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 79
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18073599
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/073599 | CYTOKINE-BASED MULTI-EPITOPE PROTEIN FOR BINDING TO CCR7-POSITIVE CELLS | Dec 1, 2022 | Abandoned |
Array
(
[id] => 18852724
[patent_doc_number] => 11850276
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-12-26
[patent_title] => Interleukin-18 variants and methods of use
[patent_app_type] => utility
[patent_app_number] => 18/060816
[patent_app_country] => US
[patent_app_date] => 2022-12-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 56
[patent_figures_cnt] => 83
[patent_no_of_words] => 59081
[patent_no_of_claims] => 31
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 402
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18060816
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/060816 | Interleukin-18 variants and methods of use | Nov 30, 2022 | Issued |
Array
(
[id] => 18321534
[patent_doc_number] => 20230119662
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-04-20
[patent_title] => ANTI-VEGF PROTEIN COMPOSITIONS AND METHODS FOR PRODUCING THE SAME
[patent_app_type] => utility
[patent_app_number] => 17/994223
[patent_app_country] => US
[patent_app_date] => 2022-11-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 67611
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -28
[patent_words_short_claim] => 191
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17994223
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/994223 | Anti-VEGF protein compositions and methods for producing the same | Nov 24, 2022 | Issued |
Array
(
[id] => 18522959
[patent_doc_number] => 20230233609
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-07-27
[patent_title] => THERAPEUTIC PROTEIN COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME
[patent_app_type] => utility
[patent_app_number] => 18/053203
[patent_app_country] => US
[patent_app_date] => 2022-11-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15615
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18053203
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/053203 | THERAPEUTIC PROTEIN COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME | Nov 6, 2022 | Pending |
Array
(
[id] => 18529932
[patent_doc_number] => 20230234999
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-07-27
[patent_title] => PRODUCTION OF RECOMBINANT LUBRICIN
[patent_app_type] => utility
[patent_app_number] => 17/975572
[patent_app_country] => US
[patent_app_date] => 2022-10-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10643
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17975572
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/975572 | Production of recombinant lubricin | Oct 26, 2022 | Issued |
Array
(
[id] => 20492642
[patent_doc_number] => 12534505
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2026-01-27
[patent_title] => Activatable interleukin-2 polypeptides and methods of use thereof
[patent_app_type] => utility
[patent_app_number] => 18/045160
[patent_app_country] => US
[patent_app_date] => 2022-10-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 48
[patent_figures_cnt] => 95
[patent_no_of_words] => 30134
[patent_no_of_claims] => 9
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 309
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18045160
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/045160 | Activatable interleukin-2 polypeptides and methods of use thereof | Oct 8, 2022 | Issued |
Array
(
[id] => 18391384
[patent_doc_number] => 20230159602
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-05-25
[patent_title] => ENGINEERED OPTIMIZED CYTOKINE COMPOSITIONS
[patent_app_type] => utility
[patent_app_number] => 17/937005
[patent_app_country] => US
[patent_app_date] => 2022-09-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8354
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 48
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17937005
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/937005 | ENGINEERED OPTIMIZED CYTOKINE COMPOSITIONS | Sep 29, 2022 | Abandoned |
Array
(
[id] => 18391429
[patent_doc_number] => 20230159647
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-05-25
[patent_title] => METHODS FOR TREATING ALLERGY AND ENHANCING ALLERGEN-SPECIFIC IMMUNOTHERAPY BY ADMINISTERING AN IL-4R INHIBITOR
[patent_app_type] => utility
[patent_app_number] => 17/935003
[patent_app_country] => US
[patent_app_date] => 2022-09-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9283
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17935003
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/935003 | METHODS FOR TREATING ALLERGY AND ENHANCING ALLERGEN-SPECIFIC IMMUNOTHERAPY BY ADMINISTERING AN IL-4R INHIBITOR | Sep 22, 2022 | Abandoned |
Array
(
[id] => 18212131
[patent_doc_number] => 20230058395
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-02-23
[patent_title] => METHODS FOR TREATING ATOPIC DERMATITIS BY ADMINISTERING AN IL-4R ANTAGONIST
[patent_app_type] => utility
[patent_app_number] => 17/951987
[patent_app_country] => US
[patent_app_date] => 2022-09-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 53739
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 229
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17951987
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/951987 | Methods for treating atopic dermatitis by administering an IL-4R antagonist | Sep 22, 2022 | Issued |
Array
(
[id] => 18294531
[patent_doc_number] => 20230104217
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-04-06
[patent_title] => FUSION PROTEIN COMPRISING IL-2 PROTEIN AND CD80 PROTEIN, AND USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/948894
[patent_app_country] => US
[patent_app_date] => 2022-09-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 25680
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 103
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17948894
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/948894 | FUSION PROTEIN COMPRISING IL-2 PROTEIN AND CD80 PROTEIN, AND USE THEREOF | Sep 19, 2022 | Pending |
Array
(
[id] => 20129200
[patent_doc_number] => 12371502
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-07-29
[patent_title] => Antibodies directed against CD127
[patent_app_type] => utility
[patent_app_number] => 17/941885
[patent_app_country] => US
[patent_app_date] => 2022-09-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 28
[patent_figures_cnt] => 28
[patent_no_of_words] => 30731
[patent_no_of_claims] => 21
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 158
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17941885
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/941885 | Antibodies directed against CD127 | Sep 8, 2022 | Issued |
Array
(
[id] => 20771523
[patent_doc_number] => 12655183
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2026-06-16
[patent_title] => Methods and compositions for treating and/or preventing a disease or disorder associated with abnormal level and/or activity of the IFP35 family of proteins
[patent_app_type] => utility
[patent_app_number] => 17/930635
[patent_app_country] => US
[patent_app_date] => 2022-09-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 58
[patent_figures_cnt] => 126
[patent_no_of_words] => 32102
[patent_no_of_claims] => 2
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 229
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17930635
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/930635 | Methods and compositions for treating and/or preventing a disease or disorder associated with abnormal level and/or activity of the IFP35 family of proteins | Sep 7, 2022 | Issued |
Array
(
[id] => 20157015
[patent_doc_number] => 12383613
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-08-12
[patent_title] => Recombinant antigen and method of making the same, isolated polynucleotide of porcine reproductive and respiratory syndrome virus (PRRSV) and immunogenic composition including the same
[patent_app_type] => utility
[patent_app_number] => 17/930168
[patent_app_country] => US
[patent_app_date] => 2022-09-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 10
[patent_figures_cnt] => 13
[patent_no_of_words] => 0
[patent_no_of_claims] => 16
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 37
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17930168
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/930168 | Recombinant antigen and method of making the same, isolated polynucleotide of porcine reproductive and respiratory syndrome virus (PRRSV) and immunogenic composition including the same | Sep 6, 2022 | Issued |
Array
(
[id] => 18537538
[patent_doc_number] => 20230242636
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-08-03
[patent_title] => MONOCLONAL ANTIBODIES TARGETED TO HUMAN TAXILIN ALPHA AND METHODS FOR USE OF SAME
[patent_app_type] => utility
[patent_app_number] => 17/930028
[patent_app_country] => US
[patent_app_date] => 2022-09-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4046
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -3
[patent_words_short_claim] => 32
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17930028
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/930028 | MONOCLONAL ANTIBODIES TARGETED TO HUMAN TAXILIN ALPHA AND METHODS FOR USE OF SAME | Sep 5, 2022 | Abandoned |
Array
(
[id] => 18273724
[patent_doc_number] => 11612645
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-03-28
[patent_title] => IL-15-based fusions to IL-12 and IL-18
[patent_app_type] => utility
[patent_app_number] => 17/820980
[patent_app_country] => US
[patent_app_date] => 2022-08-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 21
[patent_figures_cnt] => 32
[patent_no_of_words] => 30057
[patent_no_of_claims] => 4
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 88
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17820980
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/820980 | IL-15-based fusions to IL-12 and IL-18 | Aug 18, 2022 | Issued |
Array
(
[id] => 18522958
[patent_doc_number] => 20230233608
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-07-27
[patent_title] => REGULATED BIOCIRCUIT SYSTEMS
[patent_app_type] => utility
[patent_app_number] => 17/888808
[patent_app_country] => US
[patent_app_date] => 2022-08-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 70310
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 93
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17888808
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/888808 | REGULATED BIOCIRCUIT SYSTEMS | Aug 15, 2022 | Abandoned |
Array
(
[id] => 18037576
[patent_doc_number] => 20220381792
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-12-01
[patent_title] => METHOD FOR DIAGNOSING AND TREATING FIBROMYALGIA
[patent_app_type] => utility
[patent_app_number] => 17/885829
[patent_app_country] => US
[patent_app_date] => 2022-08-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7040
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -46
[patent_words_short_claim] => 45
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17885829
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/885829 | Method for diagnosing and treating fibromyalgia | Aug 10, 2022 | Issued |